Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LDL-C levels above those recommended by the National Cholesterol Education~* Program Adult Treatment Panel III (NCEP-ATP III) based on each patient risk factors following a 3-month period of lifestyle changes.~Exclusion Criteria:~* Triglycerides \>500 mg/dL, renal disease (serum creatinine levels \>1.6 mg/dL), hypothyroidism \[thyroid stimulating hormone (TSH) \>5 IU/mL\] and liver disease (ALT and/or AST levels \>3-fold upper limit of normal in 2 consecutive measurements).~* Patients with hypertension will be included in the study if they are on stable medication for at least 3 months and their blood pressure is adequately controlled (no change in their treatment will be made during the study period).~* Patients currently taking lipid lowering drugs or having stopped them less than 4 weeks before study entry will be excluded

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin 40 mg (Type: ACTIVE_COMPARATOR): All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily
- Simvastatin 10 mg plus ezetimibe 10 mg (Type: ACTIVE_COMPARATOR): All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg (n=50) or simvastatin/ezetimibe 10/10 mg (n=50) daily

Based on this trial design, predict the completion outcome and termination type (if applicable).